These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 30964161)

  • 1. MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1.
    Gong YB; Fan XH
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2366-2373. PubMed ID: 30964161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circ-PGAM1 promotes malignant progression of epithelial ovarian cancer through regulation of the miR-542-3p/CDC5L/PEAK1 pathway.
    Zhang C; Li Y; Zhao W; Liu G; Yang Q
    Cancer Med; 2020 May; 9(10):3500-3521. PubMed ID: 32167655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.
    Fan L; Lei H; Zhang S; Peng Y; Fu C; Shu G; Yin G
    Theranostics; 2020; 10(13):5895-5913. PubMed ID: 32483426
    [No Abstract]   [Full Text] [Related]  

  • 4. MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene.
    Bi L; Yang Q; Yuan J; Miao Q; Duan L; Li F; Wang S
    Oncol Rep; 2016 Nov; 36(5):2563-2570. PubMed ID: 27571744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mir-30b-3p affects the migration and invasion function of ovarian cancer cells by targeting the CTHRC1 gene.
    Li Y; Zhou J; Wang J; Chen X; Zhu Y; Chen Y
    Biol Res; 2020 Mar; 53(1):10. PubMed ID: 32156314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-127-3p inhibits proliferation of ovarian cancer in rats through down-regulating MAPK4.
    Du SY; Huang XX; Li NM; Lv CY; Lv CH; Wei ML; Gao Z; Zhang YP
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10383-10390. PubMed ID: 33155194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression.
    Zheng J; Zhou Y; Li XJ; Hu JM
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6839-6848. PubMed ID: 31486483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
    Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
    Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
    Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
    Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway.
    Zhang Y; Dun Y; Zhou S; Huang XH
    Biomed Pharmacother; 2017 Dec; 96():1216-1221. PubMed ID: 29239819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircBNC2 affects epithelial ovarian cancer progression through the miR-223-3p/ LARP4 axis.
    Lu M; Gong B; Wang Y; Li J
    Anticancer Drugs; 2023 Mar; 34(3):384-394. PubMed ID: 36730544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-505-3p mediates cell motility of epithelial ovarian cancer via suppressing PEAK1 expression.
    Wu Y; Xue L; Xiong W; Li H; Wu J; Xie W; Long Y; Liu Y; Luo C
    J Biochem Mol Toxicol; 2024 Jul; 38(7):e23767. PubMed ID: 39003575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircCERS6 Suppresses the Development of Epithelial Ovarian Cancer Through Mediating miR-630/RASSF8.
    Li X; Jiang X; Lu J; Lin Y; Jiang L; Li Y; Wan F; Wang C
    Biochem Genet; 2022 Dec; 60(6):2611-2629. PubMed ID: 35676548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-145-5p regulates the proliferation of epithelial ovarian cancer cells via targeting SMAD4.
    Zhou J; Zhang X; Li W; Chen Y
    J Ovarian Res; 2020 May; 13(1):54. PubMed ID: 32366274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-744-5p inhibits cellular proliferation and invasion via targeting ARF1 in epithelial ovarian cancer.
    Zhao LG; Wang J; Li J; Li QF
    Kaohsiung J Med Sci; 2020 Oct; 36(10):799-807. PubMed ID: 32558345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.
    Salem M; O'Brien JA; Bernaudo S; Shawer H; Ye G; Brkić J; Amleh A; Vanderhyden BC; Refky B; Yang BB; Krylov SN; Peng C
    Cancer Res; 2018 Aug; 78(15):4175-4190. PubMed ID: 29748371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircFAM188A Regulates Autophagy via miR-670-3p and ULK1 in Epithelial Ovarian Carcinoma.
    Yong M; Zeng Y; Yao Y; Yang M; Tang F; Zhu H; Hu J
    Cancer Rep (Hoboken); 2024 Sep; 7(9):e2128. PubMed ID: 39229655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
    Zhang Z; Zhang L; Wang B; Wei R; Wang Y; Wan J; Zhang C; Zhao L; Zhu X; Zhang Y; Chu C; Guo Q; Yin X; Li X
    Cancer Lett; 2020 Jan; 469():54-67. PubMed ID: 31629932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein.
    Ying X; Wei K; Lin Z; Cui Y; Ding J; Chen Y; Xu B
    Cell Physiol Biochem; 2016; 39(2):501-10. PubMed ID: 27383536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.
    Zhang L; Liu XL; Yuan Z; Cui J; Zhang H
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4663-4672. PubMed ID: 31210292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.